PARP1 and ovarian carcinoma: At BV173 and KU812 cells, combinatory apoptosis induction was also observed with the PARP-inhibitor olaparib, a medication, which is approved for treating breast and ovarian cancer by the Food and Drug Administration (FDA) [35].